<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457119</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001C2114</org_study_id>
    <secondary_id>2006-002760-26</secondary_id>
    <nct_id>NCT00457119</nct_id>
  </id_info>
  <brief_title>Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients</brief_title>
  <official_title>A Two-step Phase 1 Study Investigating the Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients
      with advanced NCLC not previously treated with systemic therapy. In step 1 of this study, RAD
      001 is given in combination with carboplatin and paclitaxel and in Step 2 RAD001 is given in
      combination with carboplatin, paclitaxel and bevacizumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-step, open-label, multi-center, dose escalation Phase 1 study in which RAD001
      is administered in combination with carboplatin and paclitaxel (CP) in Step 1 as well as
      carboplatin, paclitaxel, and bevacizumab (CPB) in Step 2 in patients with advanced
      (unresectable or metastatic) NSCLC not treated previously with systemic therapy for advanced
      disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the feasible doses/regimens of RAD001 in combination with chemotherapy. Primary endpoint is the End-of-cycle DLT rate</measure>
    <time_frame>Ever 3 months or once a critical DLT occurs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative dose intensity (RDI) of Carboplatin + Paclitaxel (step 1)</measure>
    <time_frame>End of step 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative dose intensity (RDI) of Carboplatin + Paclitaxel + bevacizumab (step 2)</measure>
    <time_frame>End of Step 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters derived from PK profiles of treatment drugs alone and in combination</measure>
    <time_frame>End of Step 1 and Step 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response - measured by CT/MRI scan every 6-8 week</measure>
    <time_frame>Every 6-8 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Step 1 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg/day RAD001 + Carboplatin + Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 1, Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg/week RAD001 + Carboplatin + Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 2, Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 2, Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm</description>
    <arm_group_label>Step 1 Arm 1</arm_group_label>
    <arm_group_label>Step 1, Arm 2</arm_group_label>
    <arm_group_label>Step 2, Arm 1</arm_group_label>
    <arm_group_label>Step 2, Arm 2</arm_group_label>
    <other_name>Everolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age over 18 years

          -  Advanced Non Small Cell Lung Cancer (Stage IIIB/IV)

          -  Ability to perform normal daily functions

        Exclusion criteria:

          -  Chronic steroid treatment

          -  Prior treatment with chemotherapy for advanced lung cancer

          -  Prior treatment with mTOR inhibitors

          -  Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers,
             eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections
             or other severe medical conditions

          -  Known sensitivity to platinum compounds, taxanes or bevacizumab

          -  Other cancers within the past 5 years

          -  Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria
             may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University/Lombardi Cancer Center StudyCoordinator:CRAD001C2114</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med. Onc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <last_update_submitted>February 9, 2013</last_update_submitted>
  <last_update_submitted_qc>February 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Advanced Lung Cancer</keyword>
  <keyword>RAD</keyword>
  <keyword>RAD001</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

